The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place
#AUA24
#EAU24
#IBCG24
#ASCO24
Designed by
@AmandaMyersMD
As I turn 50 today, I ponder the things in life I am grateful for
Clearly family, friends, and the love I receive have always been at the top of my list
But in these times, reminded how fragile life is, I can say that those are the *only* things that matter to me anymore.
Just released! Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer (SITC) and the International Bladder Cancer Group (IBCG)
@JCO_ASCO
@IBCG_BladderCA
@sitcancer
I’m getting lots of queries about whether we’re overreacting to
#COVID19
.
When all is said and done:
It will be impossible to know if we overreacted. But it will be painfully obvious if we underreacted and did too little, especially to those who lost loved ones
#Flattenthecurve
The
@Uroweb
EAU Guidelines in
#BladderCancer
are probably the most followed guidelines globally in
#OncSurgery
We are thankful for the invitation to present our 'challenges' to these guidelines - mainly our suggestions for improving what are already excellent guidelines by the
27 years strong! Grateful for my rock, my best friend, and the light in my world. Here's to many more years of love, laughter, and memories. Love you now and always! 💕
#HappyAnniversary
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
A well designed study shows equivalence of robot with open cystectomy. Notably ~67% adverse events in both groups. Emphasizing that this is a complex surgery; the ‘tool’ ie scalpel or robot less important than skill of surgeon and overall expertise of the team
@B_C_A_N
Robot-assisted radical
#cystectomy
versus open radical cystectomy in patients with
#bladdercancer
(RAZOR): an open-label, randomised, phase 3, non-inferiority trial
Just released …
Our inaugural impact factor for
@EurUrolOncol
is … 7.479
Congratulations to all our readers, authors, contributors and everyone on the EU family of journals board!
Alberto Briganti
@GGiannarini
@AlbigesL
@DrPaulNguyen
A Happy Diwali from our family to yours. 🪔 💥 🪔
May the triumph of light over darkness, good over evil, love over hate
Bring you an abundance of happiness, joy, peace and health
Now, and always
#Diwali2022
Importance of repeated stimulation of immune system with maintenance BCG has been known; forgotten; restudied; known again; forgotten; restudied again ... enough times that if someone says to you “I don’t believe in maintenance BCG” just show them the door out
#GU20
#GU2020
Plasmacytoid variant of
#BladderCancer
: a deadly disease.
Positive margin rates are 800% times that seen with conventional urothelial cancer and highly associated with mortality.
@JUrology
Our historic
@MDAndersonNews
experience with preoperative radiotherapy + radical cystectomy for
#bladdercancer
: significant impact on local control for T3b disease
Glad to see it being studied along with IO in RACE-IT and RAD- VACCINE
As of today, FDA approved
#pembrolizumab
for the treatment of BCG unresponsive, high-risk NMIBC for patients who are not eligible for or opt against undergoing cystectomy
@BladderCancerUS
Chemoradiotherapy in MIBC: 10-yr follow-up of the Phase 3 RCT BC2001 : addition of chemotherapy improved 5-yr locoregional RFS 63% vs 49% and salvage cystectomy rate from 14% vs 22%
@EmmaHall71
@Prof_Nick_James
@EUplatinum
@achoud72
Real-world data: 287 pts cN+ M0
#BladderCancer
Median OS < 2 years; ~ 20% 5 yr survival
Similar results in the RC or RT cohorts (including when restricting the analysis to patients who received NAC)
Patients treated with radical intent had better outcomes - median survival:
A touching token of appreciation from a patient (deemed incurable at several other centers 5 yrs ago). He is a surgeon himself and created this himself with the Sanskrit 'Vande Gurunam' inscribed in my initials. This is what makes it all worthwhile.
@MDAndersonNews
Meta-analysis of
#ERAS
protocols in
#bladdercancer
confirms reduced LOS and postoperative complication after radical cystectomy; association with no NG tubes and local anesthetic blocks
@EUplatinum
@EurUrolOncol
Double the celebration, double the fun!
Thrilled to witness Anant and Radhika's beautiful union and enjoy the incredible match at Wimbledon Finals.
Cheers to the happy couple, and congrats to the Wimbledon champs!
#AnantRadhikaWedding
#Wimbledon2024
"Mapping Progress in Bladder Cancer" This rapidly evolving landscape is incredibly exciting.
@UroDocAsh
@MDAndersonNews
expands on the progress in bladder cancer & an explosion of clinical trials expanding our options. Full article by
on UroToday now.
Confirmed! Men and women *are* different; even at the molecular level of
#bladdercancer
they develop: basal/squamous subtypes higher in females; luminal papillary (LumP) & neuroendocrine-like higher in males
@EurUrolOncol
@SimaPorten
@JoepJdeJong
Adherence to NMIBC guidelines ~71%.
Over treatment of low-risk disease
Overuse of UT imaging, frequent cystoscopy, & cytology.
Full text link, courtesy
@SUO_YUO
@UrolOncol
@UroOnc
From our family to yours, near and far, on the occasion of
#Diwali2021
: here’s hoping your future is full of happiness, gratitude, love, positivity, and the
#FestivalOfLights
brings you and your loved ones peace and joy, always 🪔
A Herculean effort with practice changing implications!
LNDs for
#bladdercancer
will not be the same after Monday June 5
#ASCO23
(except by those who continue to disbelieve RCTs!)
@SWOG
Clinical Validation of the Intermediate-risk NMIBC Scoring System and Substratification Model Proposed by the IBCG (International Bladder Cancer Group): A Multicenter YAU Urothelial Working Group Collaboration
@EurUrolOncol
@paolo_gontero
@frasor86
a🧵
Divergent effect of diet on the immune system
Ketogenic diet enriching for adaptive immune signatures (beneficial in cancer)
Vegan diet -> for innate immune signatures
@Nature
Post cystectomy, ctDNA analysis identified all patients with metastatic
#BladderCancer
relapse during monitoring (100% sensitivity, 98% specificity) with a median lead time of 3+ months over imaging. Implications for adjuvant trial designs
@LDyrskjot
The kindness of humanity is humbling.
My 84 yr old patient whom I called to inform that we were postponing his surveillance visit due to
#COVID19
said “yes doc, totally understand”
... then showed up later to drop off food for my clinic ... and left so as to not disturb me!
GOLDEN MOMENTS IN TELEHEALTH
“Doctor Lewis, I am grateful for the call but sorry we couldn’t have an in-person visit”
“Why is that, ma’am?”
“Because I wanted to bring food for you and your family in case you were running low”
☝️this is what will get us through.
#medtwitter
Great news for our
#bladdercancer
patients!
On December 15, 2023, the Food and Drug Administration (FDA) approved enfortumab vedotin-ejfv (Padcev, Astellas Pharma) in combination with pembrolizumab (Keytruda, Merck) for patients with locally advanced or metastatic urothelial
En bloc TURBT (for <1 cm tumors) results in
Similar recurrence rates: 18.4% vs 16.7% at 1 yr
Similar residual disease on reTUR 56% vs 55.9% (small subset)
More retrieval of DM: 80.7% vs 71.1%
Less bladder perforation: 5.6% vs 12%
Similar OR time: 26 vs 25 min
A country of 1.2 billion people goes on complete lockdown for 21 days
This despite having only 536 cases and 10 deaths from
#COVID19
This is how one deals with a pandemic!
@narendramodi
@realDonaldTrump
The evidence for role of neoadjuvant therapy in NMIBC continues to mount
2 doses of NAC with MMC reduced risk of recurrence by 63%:
@JUrology
Intensive MMC – 3/wk x 2 wks – reduced need for TURBT in 57% patients
#BladderCancer
Patient and Carer Experiences with
#BladderCancer
:
Results from this Global Survey identifies clear areas for improvement. We hope these findings will provide an evidence base to guide future initiatives that address the unmet needs of patients and their carers.